[{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"University of California, San Francisco \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Kunming Baker Norton Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Kunming Baker Norton Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kunming Baker Norton Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kunming Baker Norton Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nakhia Impex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MONGOLIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nakhia Impex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nakhia Impex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nakhia Impex \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Lumenis"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Poseidon Clinical Research Balkans LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Poseidon Clinical Research Balkans LLC","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Poseidon Clinical Research Balkans LLC"},{"orgOrder":0,"company":"Study Group for Urogenital Diseases, Italy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Oncology","graph2":"Phase II","graph3":"Study Group for Urogenital Diseases, Italy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Study Group for Urogenital Diseases, Italy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Study Group for Urogenital Diseases, Italy \/ Undisclosed"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dove Medical Press \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ Undisclosed"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dove Medical Press \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ Undisclosed"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"The Affiliated Hospital of Qingdao University | Nakhia Impex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dove Medical Press \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ Undisclosed"},{"orgOrder":0,"company":"TRB CHEMEDICA INTERNATIONAL SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TRB CHEMEDICA INTERNATIONAL SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRB CHEMEDICA INTERNATIONAL SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRB CHEMEDICA INTERNATIONAL SA \/ Undisclosed"},{"orgOrder":0,"company":"TRB CHEMEDICA INTERNATIONAL SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TRB CHEMEDICA INTERNATIONAL SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRB CHEMEDICA INTERNATIONAL SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRB CHEMEDICA INTERNATIONAL SA \/ Undisclosed"},{"orgOrder":0,"company":"NTC","sponsor":"I-MED","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NTC \/ I-MED","highestDevelopmentStatusID":"15","companyTruncated":"NTC \/ I-MED"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Wize Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Wize Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Wize Pharma \/ Bonus BioGroup","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Bonus BioGroup"},{"orgOrder":0,"company":"Ocuwize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Ocuwize","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuwize \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ocuwize \/ Undisclosed"},{"orgOrder":0,"company":"Ocuwize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuwize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuwize \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuwize \/ Undisclosed"},{"orgOrder":0,"company":"Ocuwize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuwize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuwize \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuwize \/ Undisclosed"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"||CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Anika Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BIOSYENT PHARMA INC \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"COLOMBIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes \/ Alcon Inc","highestDevelopmentStatusID":"10","companyTruncated":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes \/ Alcon Inc"},{"orgOrder":0,"company":"Eximore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Eximore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eximore \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eximore \/ Undisclosed"},{"orgOrder":0,"company":"Altacor","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Altacor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Altacor \/ Fidia Farmaceutici Spa","highestDevelopmentStatusID":"15","companyTruncated":"Altacor \/ Fidia Farmaceutici Spa"}]
Find Clinical Drug Pipeline Developments & Deals for Hyaluronate Sodium
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.
